These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28746746)

  • 1. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.
    Hamidi O; Young WF; Gruber L; Smestad J; Yan Q; Ponce OJ; Prokop L; Murad MH; Bancos I
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):440-450. PubMed ID: 28746746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients.
    Raber W; Schendl R; Arikan M; Scheuba A; Mazal P; Stadlmann V; Lehner R; Zeitlhofer P; Baumgartner-Parzer S; Gabler C; Esterbauer H
    Front Endocrinol (Lausanne); 2024; 15():1419028. PubMed ID: 39234504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
    Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
    Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology and genetics of phaeochromocytoma and paraganglioma.
    Turchini J; Cheung VKY; Tischler AS; De Krijger RR; Gill AJ
    Histopathology; 2018 Jan; 72(1):97-105. PubMed ID: 29239044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
    Gupta S; Zhang J; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
    Gagnon N; Mansour S; Bitton Y; Bourdeau I
    Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review.
    Langton K; Tufton N; Akker S; Deinum J; Eisenhofer G; Timmers H; Spaanderman M; Lenders J
    BJOG; 2021 Jul; 128(8):1264-1272. PubMed ID: 33342020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SDHA-related phaeochromocytoma and paraganglioma: review and clinical management.
    Kaplan AI; Dwight T; Luxford C; Benn DE; Clifton-Bligh RJ
    Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39133175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades.
    Goffredo P; Sosa JA; Roman SA
    J Surg Oncol; 2013 May; 107(6):659-64. PubMed ID: 23233320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
    Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features of patients with metastatic pheochromocytoma/paraganglioma].
    Cui YY; Zhou Y; Gao YJ; Li TY; Wang Y; Zhang WQ; Zhou T; Chen S; Tong AL
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1174-1179. PubMed ID: 38583049
    [No Abstract]   [Full Text] [Related]  

  • 17. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.
    van Hulsteijn LT; Niemeijer ND; Dekkers OM; Corssmit EP
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):487-501. PubMed ID: 24118038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
    Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
    Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
    Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
    J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
    Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
    Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.